By Eileen Remold-ODonnell, James Van Brocklyn, and Dianne M. Kenney The Wiskott-Aldrich syndrome (WAS) is an inherited disease involving defects of platelets (small size, severe thrombocytopenia due t o accelerated destruction) and T lymphocytes (progressive immunodeficiency, lymphopenia). The bestcharacterized molecular defect is the deficiency and, in some cases, abnormal forms of the T-lymphocyte surface mucin molecule CD43; deficiency of the platelet surface mucin GPlb was observed previously in two of four patients. Neither of these defects is primary, since CD43 and GPlb are encoded by autosomal genes and the disease is X-linked. This study uses cellular biological approaches t o explore the possibility that destruction of structurally defective WAS platelets, mimicked experimentally by sonication of normal platelets, plays a role by releasing protease and generating other cellular defects. We show that a protease of normal platelets, identified as Ca*+-dependent neutral protease (calpain), which is known t o cleave platelet GPlb, also specifically cleaves CD43
HE WISKOlT-ALDRICH syndrome (WAS) is a rare
T and severe X-linked disease involving platelets and T lymphocytes, an unusual combination of affected cells. The platelet defects are usually apparent at birth and are consistently manifested. The T-lymphocyte defects, which appear later and are progressive, include eczema, inability to generate anticarbohydrate antibodies, and susceptibility to opportunistic infections and malignant neoplasias.1-6 T-lymphocyte number and function decline with age in the WAS, with T-cell-dependent areas of the spleen and lymph nodes progressively depleted after age 5.5, 7 The thrombocytopenia in the WAS is severe. Although precursor megakaryocytes are normal in both number and ~i z e ,~,~ numbers of circulating platelets are reduced to approximately 10% of normal levels. Moreover, circulating WAS platelets are abnormally small, with an effective average diameter of 1.8 p.m compared with normal diameter of 2.2 pm.'.' Whereas normal platelets transfused in WAS patients have a normal posttransfusion half-life, transfused autologous platelets have a shortened halflife?" Circulating lymphocytes from WAS patients also have structural defects, which are detected by scanning electron microscopy as a paucity of microvillus cell surface projections." Splenectomy of WAS patients improves their on the surface of neighboring desialylated T lymphocytes. The identification of the CD43 cleaving protease was based on its requirement for Ca'+ and inhibition by leupeptin, but not by diisopropylfluorophosphate (DFP). The approximate sits of CD43 cleavage was identified by the use of a rabbit antibody. Sensitivity of GPlb t o calpain is shown to be sialylation-independent and that of CD43 t o be sialylationdependent, and these findings are explained in terms of molecular structures. These and previous findings are incorporated into a putative mechanism, which explains most of the defects in the WAS. The mechanism suggests that the primary defective molecule in the WAS is unlikely to be a surface glycoprotein, but rather a cytoplasmic molecule with a function in cytoskeletal interactions and/or calcium ion regulation and calpain activation. 0 1992 by The American Society of Hematology. platelet number." Splenectomy, moreover, alters platelet size" and lymphocyte cytoarchitecture" toward normal. Cumulatively, these findings indicate that the WAS involves a chronic pathological process, which is augmented when the spleen is present, whereby cells with structural defects, particularly platelets, are destroyed and removed from the circulation.
The combined results of two independent surface radiolabeling studies detected reduced amounts of the plateletspecific molecule GPIb in two of four WAS Study of WAS platelets is limited by their low number and small size. At present, the best-characterized molecular defect in this disease is the reduced amounts, and in some cases, abnormal molecular weight of the glycoprotein CD43 (formerly gpLll5, sialophorin, leukosialin) on WAS T lymp h~c y t e s . '~~'~~'~ Functions assigned to CD43 by in vitro studies include Ca'+-based cytoplasmic signaling," initiation of proliferation of T lymphocytes,'' and activation of monocytes'" and natural killer (NK) cells" (for CD43 review, see Remold-O'Donnell and Rosen'). Recently, anti-CD43 antibodies were shown to be frequently present in patients infected with human immunodeficiency virus type 1 (HIV-1).22 CD43 and GPIb, the two molecules shown to be defective in the WAS, have been grouped to a newly recognized family of physicochemically and structurally related molecules called "cell surface mucins," which are highly glycosylated membrane proteins containing predominantly 0-linked olig~saccharides?~ A major extracellular region of GPIbax and the entire extracellular region of CD43z-'7 are O-glycanrich regions, which form very large rod-like structures extending from the cell s~rface.~"' The proposed function of surface mucins is to preserve cells in the circulation by preventing interactions with other cells.23 Recent studies established that the defects of CD43 and GPIb are secondary rather than primary in the WAS, since these molecules are encoded by autosomal and the disease maps to the X-chromosome. The primary defective WAS molecule is unidentified.
PLATELET CALPAIN CLEAVES T-LYMPHOCYTE CD43 1755
The present study is part of an effort to advance by investigation of cell biological events from known secondary WAS defects to the primary inherited defective molecule. From a cell biological perspective, the defects that are most consistent, dramatic, and most nearly unique in the WAS are, on the one hand, the unstable nature of the platelets and their destruction and, on the other hand, the T-lymphocyte-based immunodeficiency. The present study explores the hypothesis that destruction of circulating platelets in the WAS and consequent abnormal extracellular degradative enzymes generate other cellular defects. An in vitro system using sonicated normal platelets to mimic defective and degrading WAS platelets was established to examine the effect of platelet destruction on surface proteins, particularly surface mucins, of neighboring T lymphocytes. A unifying proposal to explain WAS defects is presented in the Discussion. was used as control MoAb. Rabbit anti-CD43 antiserum has been described previo~sly.'~~" L11 is an IgG,, which reacts on flow cytometric analysis with sialidase-treated but not native blood lymphocytes (normal individuals) and sialidase-treated CEM lymphoblastoid cells and with asialo CD43 on immunoblots and immunoprecipitation (data not shown). To generate the L11 cell line, a BALB/c mouse (Cumberland View Farms, Clinton, TN) received an intraperitoneal injection of 2 x 10' sialidase-treated CEM cells (cells incubated for 10 minutes at 37°C with 5 pg/mL cycloheximide and for 40 minutes at approximately 22°C with 0.02 IUimL vibrio cholera sialidase). Additional intraperitoneal injections of 0.5 X 10' sialidase-treated cells were performed after 2 weeks and after a further 5 weeks, and intravenous injection of 2 x lo6 sialidase-treated cells after a further 17 weeks. After 3 days,
MATERIALS AND METHODS

Materials
Antibodies.
spleen cells were fused with NS-1 myeloma cells as described previously." CEM, human T-lymphoblastoid cells," were grown in Dulbecco's minimum essential medium with 4.5 mg/mL glucose, 100 U/mL penicillin, 100 pg/mL streptomycin, and 10% FCS.
Units of fresh blood anticoagulated with National Institutes of Health (NIH) formula A acid-citratedextrose (ACD) were centrifuged at 2,500 rpm for 3 minutes in a Sorvall HG rotor (DuPont Co, Wilmington, DE). Platelet-rich plasma (PRP) and buf€y coat cells (40 to 50 mL) were collected from the blood bag under pressure. Smaller volumes of blood were centrifuged at l50g for 8 minutes and separated into PRP and packed cells. All blood cell isolation was performed at room temperature in plastic or siliconized glass.
BuEy coat or total packed cells were diluted with an equal volume of Ca2+/Mg2'-free HBSS with 20 pg/mL leupeptin, and 20 mL portions were layered onto 17 mL Histopaque 1077 (Sigma Chemical) and centrifuged at 800g for 40 minutes. The interface mononuclear cells were washed one to four times in Ca2'/Mg2'-free HBSS with 2% FCS to remove contaminating platelets. Washed mononuclear cells at 5 x 10'/mL in RPMI 1640 with 2% FCS were cultured for 1 hour at 37°C in culture flasks. The nonadherent cells were collected and washed.
Platelets were isolated from PRP after addition of 0.25 vol ACD by two cycles of pelleting at 8% for 12 to 15 minutes and resuspension in 10 mmol/L, N-Tris-(hydroxymethyl) methyl-2-aminoethane sulfonic acid (TES), pH 7.2, 136 mmol/L NaCI, 2.6 mmol/L KCI, 0.5 mmol/L NaH,P04, and 2 mmol/L MgCI, (TES Tyrodes'). The platelet preparations, which were counted electronically (Model S plus IV, Coulter Electronics, Hialeah, FL), contained no detectable erythrocytes and less than one leukocyte per 2,000 platelets.
Platelets at i09/mL in ca2+-free HBSS containing 1 mmol/L EGTA and 2 mmol/L mercaptoethanol at pH 7.0 were disrupted by sonifying 17-to 20-mL aliquots at 4°C using a macrotip preparative probe at 50% duty cycle with 96 bursts of 1 second each delivered over 2 minutes (Model W-225R Sonicator, Heat Systems, Ultrasonics, Farmingdale, NY). Sonicates were freed of undisrupted platelets and large fragments by centrifugation at 20,800g for 13 minutes at 4°C and the supematant fraction frozen in 2-to 5-mL aliquots using dry iceiacetone and stored at -80°C. Undiluted platelet lysate was defined as 100 U/mL.
Lymphocytes and CEM cells at 107/mL in Ca2'/Mg2'-free HBSS were incubated with 0.02 IU/mL Vibrio cholera sialidase for 30 minutes at approximately 22"C, diluted in cold Ca2'/Mg2'-free HBSS, pelleted, and washed in Ca2+/M$-free HBSS before elastase treatment, or Ca2+-free HBSS with 1 mmol/L EGTA before calpain treatment. Washed platelets at 109/mL in TES Tyrodes' were incubated for 30 minutes at approximately 22°C with 0.08 IU/mL Vibrio cholera sialidase, diluted with TES Tyrodes' containing one-third vol ACD, pelleted, washed, and resuspended at 0.5 x 109/mL before calpain treatment.
Lymphocytes and CEM cells (native and/or sialidase-treated) at 2 x lo7 in 2 mL were preincubated for 3 minutes at 20°C with 5 to 100 U/mL of calpaincontaining platelet sonicates in Ca2+-free HBSS with 1 mmol/L EGTA, 2 mmol/L DFP, and 2 mmol/L mercaptoethanol. Replicate incubations containing 100 pg/mL leupeptin served as negative controls. CaCl, was added to 2 mmol/L excess over EGTA and incubation was continued for 5 minutes at 20°C. To terminate protease action, leupeptin was added to 100 p,g/mL and the cells Lymphoblastoid cells.
Blood fractionation.
Lymphocytes.
Platelets.
Culpain-containingplatelet lysates.
Sialidase-treatments.
Treatments of lymphoid cells.
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From were brought to 4°C and washed twice in cold Ca2+-free HBSS with 25 pg/mL leupeptin.
Lymphocytes and CEM cells at 3 x lo7 in 2 mL were incubated at 37°C for 10 minutes with porcine pancreatic elastase in HBSS with 10 pg/mL DNase I.y DFP was added to 2 mmol/L, and the cells were incubated at approximately 22°C for 3 minutes, and washed twice by diluting and pelleting in cold HBSS containing 2 mmol/L DFP.
Lymphocytes and CEM cells were lysed by adding 1 mL per 2 x lo7 cells of 0.5% Nonidet P-40.10 mmoI/LTris-HCI buffer, pH 7.4, 150 mmol/L NaCI, 3 mmol/L iodoacetamide, 50 pg/mL leupeptin, 2 mmol/L DFP, and pipetting for 3 minutes at approximately 22°C and 8 minutes at 4°C. The lysates were clarified by centrifugation at 13,000 rpm for 13 minutes at 4°C.
Sialidase-treated lymphocytes were preincubated at 107/mL in phenol red-free HBSS with 2% FCS (HBSS-FCS) at 4°C for 10 minutes and then pelleted. Sets of 106 cells were incubated in 200 pL HBSS-FCS with MoAb (ascites at OS%, culture supernatant at 30%) at 4°C for 60 minutes. The cells were washed in cold HBSS-FCS, incubated with 1.5 pg fluorescein isothiocyanate-conjugated F(ab'), of goat anti-mouse IgG (FITCgamIgG) (Tago, Burlingame, CA) in 100 WL HBSS-FCS at 4°C for 30 minutes, washed in cold phosphate-buffered saline (PBS), resuspended in 100 pL PBS at approximately 22"C, fixed with equal volume of 2% formaldehyde in PBS, and analyzed on a Coulter Epics Cytofluorograph (provided through the courtesy of Wallace H. Coulter, Coulter Electronics). Mean fluorescence channel values were converted, after subtraction of nonspecific fluorescence determined with M7 MoAb, to arbitrary linear units using a standard curve generated by parallel measurement of calibrated fluorescein-coated spherical particles (Immuno-Brite Standard Kit, Epics Division, Coulter Electronics).
Cell lysates were heated at 100°C with an equal volume of 1% SDS in 60 mmol/L Tris-glycine buffer, pH 6.8 without (CD43 experiments) or with (calpain and GPIb experiments) 4% mercaptoethanol and separated by SDS-polyacrylamide gel electrophoresis (PAGE)& on 7.5% polyacrylamide slab gels as described." Apparent molecular weight of CD43 fragments was determined by electrophoretic mobility relative to myosin, p-galactosidase, phosphorylase-a, albumin, and creatine kinase, indicating 200,000, 130,000, 94,000, 68,000, and 40,000, respectively."."
Polypeptides in acrylamide gels were transferred to 0.2 pm nitrocellulose (Schleicher & Schuell, Keene, NH) at constant 2.1 A at 4°C for 4 hours (CD43 analysis)" or 80 mA at approximately 22°C for 16 hours (analysis of calpain or GPIb).
Immunostaining with L10 MoAb and rabbit antLCD43 antiserum was as described"; immunostaining with B27D8 MoAb was as described for L10 except that ascites was diluted one to 40,000. For immunostaining of platelet GPIba, the membrane was treated with 3 wt/vol% bovine serum albumin (BSA) and 3 wt/vol% milk in 154 mmol/L NaCI, 10 mmol/L TES, pH 7.2, and 0.01% Tween-20 for 1 hour at 22"C, washed, incubated for 2 hours with P6D ascites (diluted one to 10,000) in 154 mmol/L NaCI, 10 mmol/L TES, and 0.1% BSA. After washing, the membrane was incubated with IzI-rabbit anti-mouse IgG for 2 hours, washed in 154 mmol/L NaCI, 10 mmol/L TES, 0.01% Tween 20, and 20 mmol/L NaI, dried, and exposed to film. Rabbit anti-mouse IgG was radioiodinated using IODO-GEN.47
Quuntiration. To quantify CD43 and its fragments, negatives of immunoblots were scanned and integrated on an Ultrascan XL densitometer (LKB Instruments, Rockville, MD); to quantify GPIb, autoradiographs of immunoblots were similarly scanned and integrated.
Flow cytomehic analysis.
SDS-PAGE.
Immunoblotting.
RESULTS
CD43 on sialidase-treated T-lymphoblastoid cells is cleaved
by protease of lysed platelets. To investigate the effects of their degradative enzymes, normal platelets were lysed and incubated with T-lymphoblastoid cells (CEM cells), known to express high levels of surface CD43.Is Immunoblotting of the treated cells with the anti-CD43 MoAb L10 detected no alteration of native CD43, even in cells treated with 100 U/mL of platelet lysate. In contrast, treatment with 5 to 20 U/mLof platelet lysate caused a dose-dependent disappearance of the asialo CD43 band of sialidase-treated lymphoblastoid cells (Fig 1A) . For (Fig 1B) . The loss of surface fluorescence indicated that the CD43 region encompassing the L10 epitope is released or destroyed when cells are treated with sialidase and platelet lysate.
Immunoblotting with another reagent, rabbit antLCD43 antiserum, detected the fragment of CD43, a species of apparent molecular weight 88,000, that remains associated with the cells after exposure to platelet lysate (Fig 2) . The amount of antigenic activity lost from asialo-CD43 is recovered in the molecular weight 88,000 fragment, indicating that the fragment is not further cleaved.
When examined in adjacent SDS-PAGE lanes, the fragment of asialo CD43 generated by the platelet protease did not comigrate with the previously described fragment generated by elastase (apparent molecular weight 90,000," not shown), indicating that the platelet protease and elastase cleave at nonidentical neighboring peptide bonds. Based on the apparent molecular weight of the remaining CD43 fragment, the released portion is approximately half of the extracellular region (-120 of 235 amino acids).
Cleavage of asialo CD43 by platelet lysates requires Ca2+ and is inhibited by leupeptin. Cleavage of lymphoblastoid cell asialo CD43 by platelet lysates was time-dependent over the range 1,3, and 5 minutes at 20°C and temperaturedependent, increasing over the range 0", lo", and 20", but decreased at 37°C (not shown), possibly due to degradation of the platelet protease. Cleavage of asialo CD43 by platelet lysates was completely dependent on Ca" and inhibited by the cysteine protease inhibitor leupeptin, but not by the serine protease inhibitor DFP (Fig 3) , strongly indicating that the enzyme in platelet lysates responsible for cleaving asialo CD43 is Ca2+-dependent neutral protease.
Ca2'-dependent neutral protease (calpain) is a ubiquitous enzyme thought to participate in Ca2+-mediated events such as cell adhesion," exocytosis,4' and late phases of platelet activatior~'~.~"~~ by limited cleavage of selected proteins?' It is generally found in the cytoplasm as the inactive proenzyme,54 which during Cell-associated fragment of asialo CD43.
Calpain content of platelet lysates.
-' --, . -. Ca*'-mediated signaling undergoes autoproteolysis, generating the active but short-lived calpain molecule.s5
The platelet lysates were examined for content of calpain. Greater than 90% of the total p,-calpain in sonicated platelets was found in the soluble fraction (called platelet lysate) (not shown). It was present entirely as the inactive precursor, procalpain, and on incubation with Ca" under the conditions of the lymphoid cell incubations, was quantitatively converted to active calpain with altered molecular weight (Fig 4) ; the generation of active calpain in platelet lysates was also demonstrated by the time-dependent cleavage of the endogenous substrates actin-binding protein and talins6 detected on parallel Coomassie blue-stained SDS-
PAGE gels (not shown).
Asialo CD43 on lymphocytes cleaved by platelet calpain. The platelet lysates also cleaved sialidase-treated, but not native, CD43 on normal blood lymphocytes as indicated by loss of the L10 epitope on flow cytometric analysis (not shown) and loss of the characteristic band on L10 immunoblots of cells (not shown) and on rabbit anti-CD43 immuno- blots (Fig 5) . Rabbit anti-CD43 immunoblots detected also the calpain-generated lymphocyte-associated asialo CD43 fragment of apparent molecular weight 88,000 (Fig 5) .
Although the rabbit anti-CD43 antiserum reacts with other T-lymphocyte proteins, the CD43 fragment could be identified based on its appearance coincident with loss of the CD43 band. Cleavage of asialo CD43 on lymphocytes by platelet lysates is dose-dependent (Fig 5) , Ca2+ requiring, inhibited by leupeptin and DFP-insensitive (not shown).
To determine whether desialylated CD43 is a specific substrate for calpain, other T-lymphocyte surface proteins were examined by flow cytometry with a panel of MoAbs. Treatment of lymphocytes with sialidase and 20 U/mL calpain reduced the surface density of L10 epitopes on CD43 molecules by 51% relative to control lymphocytes (mean of three experiments). The loss was much less for epitopes of CD3, CD4,
Spec@city of CD43 cleavage.
CD2, HLA, CD45, CD18, CDlla, CDllb, and L8 antigen (Fig 6) , indicating that desialylated CD43 is a specific calpain substrate. Platelet GPIb is an established, specific substrate for ~alpain.~'.~~ The effect was examined of the calpain-containing platelet lysates on GPIb of native and sialidase-treated target platelets. Sialidase removes negative charge from GPIba, shifting its apparent molecular weight from 140,000 to 155,000. Calpain at 10 to 50 U/ml caused a dose-dependent loss of native GPIba and asialo GPIba from the platelet surface. No difference was detected in the sensitivity to calpain cleavage of asialo GPIba and native GPIba (Fig 7) .
Cleavage of platelet GPIb by platelet calpain.
DISCUSSION
This study demonstrates that calpain released by disrupting normal platelets cleaves CD43 on neighboring desialylated T lymphocytes, releasing the N-terminal region, which mediates cytoplasmic signaling and lymphocyte proliferation. Cleavage occurs in the presence of other products of lysed platelets. The short-lived platelet protease, which cleaves asialo CD43 and also native and asialo GPIb on platelets, was identified as calpain, since it requires Ca2+ and is inhibitable by leupeptin, but not DFP. Although p,-calpain (calpain I) activity was monitored, platelets also contain m-calpain (calpain II):S5y.M and there is no evidence to identify the specific calpain(s) responsible for cleavage, since both are likely activated under the experimental conditions.
Epitopes of nine other surface molecules were only minimally altered when lymphocytes were treated with the calpain-containing platelet lysates, indicating that desialylated CD43 is a specific substrate. These findings establish the basis for proposed events in the WAS. Despite normal platelet production, the decrease of circulating WAS platelets to approximately 10% of normal levels indicates a vigorous process of platelet destruction. Destruction of WAS platelets, mimicked in this study by sonication of normal platelets, releases procalpain, which is converted on contact with Ca" to active calpain, which specifically cleaves platelet GPIb and desialylated CD43 on lympho- cytes. It is likely that only neighboring cells are affected, since released active calpain is rapidly degradeds4 at 3PC in the presence of Ca2+ (experiments similar to Fig 4, data not shown). Although calpain is ubiquitous, it is nonetheless suspected as a cause of defects in the WAS, because its levels are particularly high in platelets. bo Whereas native and asialo GPIb and asialo CD43 were readily cleaved by low calpain levels, native (sialylated) CD43 was not cleaved by the highest calpain level tested, indicating at least 25-fold lesser sensitivity. The sialylationindependence of GPIb cleavage and sialylation-dependence of CD43 cleavage are understandable based on the molecular structures and locations of the cleavage sites. Calpain cleaves GPIb within the non-or minimally glycosylated 33-amino acid region located between the cell surface and the 0-glycan-rich region61*62 (Fig 8) . In T-lymphocyte CD43, the nonglycosylated region between the cell surface and the mucin region is only approximately 12 amino acids in length and is not the site of calpain cleavage (Fig 8) .
Sialidases are known to be normal components of the mammalian circulatory system; they act, for example, on the erythrocyte surface mucin glycophorin in the process of cell senescence.6' These sialidases, located in the blood vessel walls and possibly enriched in the spleen, are thought to act on CD43 and GPIb to produce transiently present desialylated molecules. However, sialidase levels in the circulatory system of WAS individuals are probably normal. Examination of circulating lymphocytes with L11 MoAb, specific for sialidase-treated CD43, failed to detect asialo CD43 on cells from normal individuals or from WAS patients (unpublished findings). Likewise, Piller et a1 isolated 0-glycans and found no indications for WAS T-lymphocyte CD43 molecules lacking sialic acid.I6 The strongest evidence that sialidases are normal in WAS patients is the nature of the disease as a single defect correctable by transplantation of hematopoietic stem cells. We tentatively conclude that excess calpain, released from blood cells, acts to cleave T-lymphocyte CD43 despite mechanisms that favor the preservation of sialylation of blood cell surface mucins including possible resialylation mechanisms that have been demonstrated for tumor cell surface mucins.@ The finding that released calpain is sufficient to cleave platelet GPIb, but that T-lymphocyte CD43 is subject to an additional constraint, is consistent with the vigorous destruction of platelets in the WAS and the lesser and later attrition of T lymphocytes.
Findings in the WAS. Anticipated findings based on the proposed WAS model are (1) that patient circulating lymphocytes would have reduced CD43 levels and (2) likely have detectable levels of the molecular weight 88,000 CD43 fragment, and (3) that WAS platelets might have abnormal levels of calpain. The first prediction has been amply documented. Studies from several laboratories reported the deficiency of CD43 of apparent molecular weight 115,000 on circulating T lymphocytes of WAS patient^.^""^'^ In addition, CD43 molecules of apparent molecular weight 135,000 were found on circulating lymphocytes of some WAS patients by surface labeling,I5 surface fluorescence, and immunoblotting.16 CD43 of molecular weight 135,000, which is the CD43 species expressed on activated normal T lymphocytes, carries predominantly 0-linked hexasaccharides and differs in this respect from molecular weight 115,000 CD43 of normal circulating T lymphocytes, which carries predominantly 0-linked tetra~accharides.6~ Circulating T lymphocytes of WAS patients do not express other markers of T-cell activation.I6 Although the proteolytic sensitivity of "hexasaccharide CD43" and "tetrasaccharide CD43" has not been compared, it is possible that CD43 GPIbs For personal use only. on August 30, 2017. by guest www.bloodjournal.org From the shift toward hexasaccharide CD43 expression on circulating T lymphocytes of some WAS patients reflects a selection process whereby T cells with hexasaccharide CD43 have greater survival capacity in the WAS circulation.
The second prediction, the possible presence of the molecular weight 88,000 CD43 fragment on circulating WAS lymphocytes cannot be examined at this time because of the lack of an appropriate antibody. Characterized anti-CD43 MoAbs do not react with the molecular weight 88,000 CD43 fragment, and the rabbit antiserum used in the present study is not sufficiently specific for the purpose.
In a study in which whole blood from WAS patients was stored overnight, tetrasaccharide CD43 (molecular weight 115,000 CD43) was lost from T lymphocytes on storage of blood and small amounts of higher molecular weight (135,000) and lower molecular weight (95,000) CD43 species were generated.a The lower molecular weight species were detected with L10 MoAb,6* and therefore are not identical to the molecular weight 88,000 calpain-generated CD43 fragment, which lacks the N-terminus with the L10 epitope. However, the dramatic finding of the storage experiments, the nearly complete loss of molecular weight 115,000 CD43 (tetrasaccharide CD43) on WAS lymphocytes when they were stored overnight in whole WAS blood, strongly supports the hypothesis that T-lymphocyte CD43 is cleaved in vivo by protease released from degrading WAS platelets.
As to the third prediction involving calpain, immunoblot and activity assays demonstrated that procalpain levels are significantly decreased in platelets of WAS patients relative to normal platelets (Kenney et al, manuscript in preparation). Active calpain was nondetectable in both normal and WAS platelets. The finding of decreased procalpain levels in WAS platelets, together with the knowledge that activated calpain is rapidly degraded, suggests that procalpain becomes depleted in circulating WAS platelets as a consequence of inappropriate activation. Abnormal platelet calpain levels have been documented in other thrombocytopenias, including thrombotic thrombocytopenic purpura (active extracellular calpain)ffl and Montreal platelet syndrome (decreased procalpain levels; large platelet^).^'
The hypothesis that WAS cells, particularly platelets, are abnormally susceptible to calpain activation is also consistent with the recent documentation of a microvesiculation process involving the loss of cell mass from normal plate-lets. Calpain activation in normal platelets, occurring as either an immediate response to ionophore or a late response of aggregation, correlates with release of microvesi c l e~.~~,~~ In certain instances, microvesicle release is inhibited by calpain inhibitors and correlates with cleavage of calpain-sensitive cytoskeletal proteins, particularly actinbinding protein. Moreover, the process includes cleavage of GPIb and its release from the platelet s~rface.~' The phenomenon of calpain-induced release of microvesicles from normal platelets provides a putative link for the observed defects in the WAS, namely the depletion of platelet procalpain, the decrease of platelet GPIb in some patients, and the decreased mass of circulating platelets.
These combined findings establish a plausible scenario in the WAS in which defective platelets (and possibly T lymphocytes) have abnormal cytoarchitecture and enhanced susceptibility to procalpain activation. Inappropriately generated active calpain cleaves cytoskeletal molecules causing loss of mass from platelets (and possibly from T lymphocytes) by release of microvesicles and further degradative events mediated by extracellular active calpain, which cleaves GPIb on platelets and CD43 on desialylated T lymphocytes. This hypothesis strongly suggests that the primary defective molecule in the WAS is not a surface glycoprotein, but rather a cytoplasmic component involved in cytoskeletal interactions and/or calcium ion regulation and calpain activation.
This proposal of events in the WAS appears complicated only because we are viewing it from the perspective of known downstream secondary defects. An essentially parallel scenario has been postulated for Duchenne's and Becker's muscular dystrophy, in which inheritance of a defective cytoskeletal component leads via enhanced susceptibility to proteolytic events, possibly involving abnormal Ca" regulation and calpain activation, to cleavage of the associated cell surface mucin and progressive destruction of affected cells.73
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